Metsera
PrivateLast Round
M&A
Nov 13, 2025
Est. Valuation
$7B
Total Funding Raised
$505M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Metsera is a biopharmaceutical company focused on developing innovative therapies for obesity and metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Government Contracts, Hardware Sales, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Metsera Comparables
Compare Metsera with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kailera Therapeutics | 86% | |
| Viking Therapeutics, Inc. | 84% | |
| Verdiva Bio | 82% |
For institutional investors. Book with your work email.
Metsera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| M&A | Nov 13, 2025 | ||||
| IPO | Feb 3, 2025 | ||||
| Series B | Nov 12, 2024 | ||||
| Series A | Apr 18, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Metsera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Newpath Partners | Series B, Series A |
| Evercore ISI | IPO |
| Janus Henderson Group | Series B |
| SoftBank Investment Advisers | Series B, Series A |
| SymBiosis Capital Management | Series B |
| RA Capital Management | Series B |
| GV | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 10, 2025
Novo Nordisk withdrew its offer, allowing Pfizer to proceed.
- Nov 5, 2025
Injectable version of MET-097 in Phase IIb trial.
For institutional investors. Book with your work email.
Metsera Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Appears On
Curated lists and screens where this company is featured.
Frequently Asked Questions
Common questions about Metsera's valuation, stock price, and market status.
Is Metsera a public or private company?
Metsera is a private company.
What is the current stock price of Metsera?
Metsera is a private company, so its shares have no public market price. Caplight tracks Metsera's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Metsera worth (valuation)?
Metsera's valuation is estimated at $7.0B based on funding round data.
Can I buy Metsera stock?
Metsera shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Metsera's last funding round?
Metsera's most recent funding round was M&A on November 13, 2025.
Who are the main investors in Metsera?
Key investors in Metsera include Evercore ISI, Guggenheim Securities, BofA Securities, ARCH Venture Partners, Wellington Management.
Will Metsera IPO soon?
No public IPO plans have been announced for Metsera.
How can I track Metsera secondary market activity?
Caplight tracks bids, offers, and trades in Metsera's shares on secondary markets.